These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 20847214)

  • 21. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
    Dong B; Zhang Y; Fu X; Wang G
    Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
    [No Abstract]   [Full Text] [Related]  

  • 22. Quantification of JAK2V617F mutation by next-generation sequencing technology.
    Abdelhamid E; Figeac M; Renneville A; Quief S; Villenet C; Boyer T; Nibourel O; Coiteux V; Cassinat B; Lippert E; Helevaut N; Soua Z; Preudhomme C
    Am J Hematol; 2013 Jun; 88(6):536-7. PubMed ID: 23553621
    [No Abstract]   [Full Text] [Related]  

  • 23. [Progress of study on JAK2V617F mutation in myeloproliferative neoplasm].
    Chen YX; Li Y; Zhang LY; Liu B
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Oct; 19(5):1329-33. PubMed ID: 22040998
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A novel quantitative JAK2V617F detection kit: prospective clinical performance study comparing MPN patients and healthy subjects].
    Kirito K; Koike M; Noguchi M; Kizaki M; Katayama N; Sugimoto Y; Dobashi N; Usui N; Komatsu N
    Rinsho Ketsueki; 2018; 59(6):669-674. PubMed ID: 29973441
    [TBL] [Abstract][Full Text] [Related]  

  • 25. JAK2V617F allele burden, JAK2 46/1 haplotype and clinical features of Chinese with myeloproliferative neoplasms.
    Wang J; Xu Z; Liu L; Gale RP; Cross NC; Jones AV; Qin T; Ai X; Xu J; Zhang T; Sun X; Li Q; Zhang P; Zhang Y; Xiao Z
    Leukemia; 2013 Aug; 27(8):1763-7. PubMed ID: 23337930
    [No Abstract]   [Full Text] [Related]  

  • 26. Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib.
    Pacilli A; Fanelli T; Mannarelli C; Rotunno G; Pancrazzi A; Vannucchi AM; Guglielmelli P
    Hematol Oncol; 2018 Feb; 36(1):357-359. PubMed ID: 28474777
    [No Abstract]   [Full Text] [Related]  

  • 27. JAK2V617F mutation is ubiquitously present in splanchnic vein thrombosis accompanying myeloproliferative syndromes.
    Kanellopoulou T; Alexopoulou A; Koskinas J
    Aliment Pharmacol Ther; 2011 Jun; 33(12):1382-3. PubMed ID: 21569067
    [No Abstract]   [Full Text] [Related]  

  • 28. Melting curve analysis after T allele enrichment (MelcaTle) as a highly sensitive and reliable method for detecting the JAK2V617F mutation.
    Morishita S; Takahashi K; Araki M; Hironaka Y; Sunami Y; Edahiro Y; Tsutsui M; Ohsaka A; Tsuneda S; Komatsu N
    PLoS One; 2015; 10(3):e0122003. PubMed ID: 25794279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The JAK2V617F mutation in polycythemia vera and other myeloproliferative disorders: one mutation for three diseases?
    James C
    Hematology Am Soc Hematol Educ Program; 2008; ():69-75. PubMed ID: 19074061
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK2V617F mutation as a marker of a latent myeloproliferative disorder in a patient with Budd-Chiari syndrome and factor V Leiden mutation.
    Plumé G; Vayá A; Ferrando F; Mira Y; Orbis F
    Thromb Haemost; 2007 Sep; 98(3):681-2. PubMed ID: 17849060
    [No Abstract]   [Full Text] [Related]  

  • 31. Oncogenic JAK2V617F requires an intact SH2-like domain for constitutive activation and induction of a myeloproliferative disease in mice.
    Gorantla SP; Dechow TN; Grundler R; Illert AL; Zum Büschenfelde CM; Kremer M; Peschel C; Duyster J
    Blood; 2010 Nov; 116(22):4600-11. PubMed ID: 20696946
    [TBL] [Abstract][Full Text] [Related]  

  • 32. JAK2 V617F gene mutation in the laboratory work-up of myeloproliferative disorders: experience of a major referral center in Lebanon.
    Mahfouz RA; Hoteit R; Salem Z; Bazarbachi A; Mugharbel A; Farhat F; Ziyadeh A; Ibrahim A; Taher A
    Genet Test Mol Biomarkers; 2011 Apr; 15(4):263-5. PubMed ID: 21198321
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Repeat
    Kearney L; Lee Tokar L; Flynn C; Mykytiv V; Murphy K; Langabeer SE
    J Clin Pathol; 2020 Nov; 73(11):772. PubMed ID: 32646925
    [No Abstract]   [Full Text] [Related]  

  • 34. Budd Chiari syndrome and V617F/JAK 2 mutation linked with the myeloproliferative disorders.
    Smira G; Gheorghe L; Iacob S; Coriu D; Gheorghe C
    J Gastrointestin Liver Dis; 2010 Mar; 19(1):108-9. PubMed ID: 20361090
    [No Abstract]   [Full Text] [Related]  

  • 35. [JAK2V617F mutation in the patients with myeloproliferative disorder and its relation with clinical characteristics].
    Zhu JF; Liu Y; Liu P; Jia MF; Cheng J; Zhao L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2011 Aug; 19(4):916-20. PubMed ID: 21867614
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Concomitant presence of JAK2V617F mutation and BCR‑ABL translocation in two patients: A new entity or a variant of myeloproliferative neoplasms (Case report).
    Mousinho F; Azevedo AP; Mendes T; Santos PSE; Cerqueira R; Matos S; Santos S; Ramos S; Viana JF; Lima F
    Mol Med Rep; 2018 Jul; 18(1):1001-1006. PubMed ID: 29845291
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of JAK2V617F Mutational Status on Phenotypic Features in Essential Thrombocythemia and Primary Myelofibrosis.
    Yönal İ; Dağlar-Aday A; Akadam-Teker B; Yılmaz C; Nalçacı M; Yavuz AS; Sargın FD
    Turk J Haematol; 2016 Jun; 33(2):94-101. PubMed ID: 25913509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [High resolution melting analysis for detecting of JAK2V617F mutation in patients with myeloproliferative neoplasms].
    Chen HH; Yang JL; Lu HF; Zhou WJ; Yao F; Deng L
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Feb; 22(1):112-6. PubMed ID: 24598662
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [The discovery of JAK2 mutation has changed the diagnostic criteria of myeloproliferative neoplasms].
    Zhu P
    Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(25):1729-31. PubMed ID: 19035079
    [No Abstract]   [Full Text] [Related]  

  • 40. [Expression of JAK2V617F and MPLW515L/K mutation in 30 suspected cases of early myeloproliferative disorders].
    Fan Z; Zhang R; Shen YM; Fei HR; Zhu ZL; Cen JN
    Zhonghua Xue Ye Xue Za Zhi; 2008 Sep; 29(9):611-4. PubMed ID: 19175989
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.